Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study

Inflammatory Bowel Diseases

Volumn 21, Issue 10, 2015, Pages 2247-2253

  Eser, Alexander ^a   Colombel, Jean Frederic ^b   Rutgeerts, Paul ^c   Vermeire, Severine ^c   Vogelsang, Harald ^a   Braddock, Martin ^d   Persson, Tore ^e   Reinisch, Walter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d ASTRAZENECA   (United Kingdom)

^e ASTRAZENECA R AND D   (Sweden)

Author keywords

abdominal pain; Crohn's disease; inflammatory bowel disease; oral P2X7 inhibitor; randomized controlled trial

Indexed keywords

ANTIINFLAMMATORY AGENT; AZATHIOPRINE; AZD 9056; C REACTIVE PROTEIN; CALGRANULIN; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; OLSALAZINE; PLACEBO; PURINERGIC P2X RECEPTOR ANTAGONIST; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG; ADAMANTANE; AZD9056; BENZAMIDE DERIVATIVE; BIOLOGICAL MARKER;

ADULT; ARTICLE; CLINICAL ARTICLE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CROHN DISEASE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FECES ANALYSIS; FECES LEVEL; FEMALE; HEMATOLOGIC DISEASE; HUMAN; INFESTATION; LOW VISION; LYMPHATIC SYSTEM DISEASE; MALE; MENTAL DISEASE; METABOLIC DISORDER; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SHORT FORM 36; VERTIGO; WELLBEING; ANALOGS AND DERIVATIVES; CHEMISTRY; CLINICAL TRIAL; FECES; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PSYCHOLOGY; QUALITY OF LIFE; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADAMANTANE; ADMINISTRATION, ORAL; ADULT; BENZAMIDES; BIOMARKERS; C-REACTIVE PROTEIN; CROHN DISEASE; DOUBLE-BLIND METHOD; FECES; FEMALE; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; PURINERGIC P2X RECEPTOR ANTAGONISTS; QUALITY OF LIFE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 84942257551     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000514     Document Type: Article

References (18)

1. Burnstock G. Purinergic receptors. J Theor Biol. 1976;62:491-503.
2. Antonioli L, Colucci R, Pellegrini C, et al. The role of purinergic pathways in the pathophysiology of gut diseases: pharmacological modulation and potential therapeutic applications. Pharmacol Ther. 2013;139:157-188.
3. Arulkumaran N, Unwin RJ, Tam FW. A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases. Expert Opin Investig Drugs. 2011;20:897-915.
4. Monteleone G, Trapasso F, Parrello T, et al. Bioactive IL-18 expression is up-regulated in Crohn's disease. J Immunol. 1999;163:143-147.
5. Pizarro TT, Michie MH, Bentz M, et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. J Immunol. 1999;162:6829-6835.
6. Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol. 1993;94:174-181.
7. Hasko G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. Trends Immunol. 2004;25:33-39.
8. Sanchez-Munoz F, Dominguez-Lopez A, Yamamoto-Furusho JK. Role of cytokines in inflammatory bowel disease. World J Gastroenterol. 2008; 14:4280-4288.
9. Gulbransen BD, Bashashati M, Hirota SA, et al. Activation of neuronal P2X7 receptor-pannexin-1 mediates death of enteric neurons during colitis. Nat Med. 2012;18:600-604.
10. Keating C, Pelegrin P, Martinez CM, et al. P2X7 receptor-dependent intestinal afferent hypersensitivity in a mouse model of postinfectious irritable bowel syndrome. J Immunol. 2011;187:1467-1474.
11. Chessell IP, Hatcher JP, Bountra C, et al. Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain. 2005;114:386-396.
12. Clark AK, Staniland AA, Marchand F, et al. P2X7-dependent release of interleukin-1beta and nociception in the spinal cord following lipopolysaccharide. J Neurosci. 2010;30:573-582.
13. Bradley HJ, Baldwin JM, Goli GR, et al. Residues 155 and 348 contribute to the determination of P2X7 receptor function via distinct mechanisms revealed by single-nucleotide polymorphisms. J Biol Chem. 2011;286: 8176-8187.
14. Sorge RE, Trang T, Dorfman R, et al. Genetically determined P2X7 receptor pore formation regulates variability in chronic pain sensitivity. Nat Med. 2012;18:595-599.
15. Alcaraz L, Baxter A, Bent J, et al. Novel P2X7 receptor antagonists. Bioorg Med Chem Lett. 2003;13:4043-4046.
16. Baxter A, Bent J, Bowers K, et al. Hit-to-Lead studies: the discovery of potent adamantane amide P2X7 receptor antagonists. Bioorg Med Chem Lett. 2003;13:4047-4050.
17. Furber M, Alcaraz L, Bent JE, et al. Discovery of potent and selective adamantane-based small-molecule P2X(7) receptor antagonists/interleukin-1beta inhibitors. J Med Chem. 2007;50:5882-5885.
18. Keystone EC, Wang MM, Layton M, et al. Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann Rheum Dis. 2012;71:1630-1635.